Autoimmunity, Antibody, Autoimmune disease, Immune system, Autoimmune diseases, Drug

Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca

On Feb 1, 2021
@BentheFidler shared
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca https://t.co/G8rcOAm6e1 with @realJacobBell $VIE $HZNP $AZN
Open

AstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million. 

www.biopharmadive.com
On Feb 1, 2021
@BentheFidler shared
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca https://t.co/G8rcOAm6e1 with @realJacobBell $VIE $HZNP $AZN
Open

Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca

Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca

AstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million. 

Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs

Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs

Horizon Therapeutics has struck a $3 billion deal to buy AstraZeneca spinout Viela Bio. The takeover will give Horizon a clutch of clinical-phase autoimmune and inflammatory disease drug ...

Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

- Conference Call Today at 8 a.m. EST to Discuss Transaction -- Provides TEPEZZA® (teprotumumab-trbw) Supply Update; Submitted Prior Approval Supplement to FDA to Support Increased Scale ...

Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease

Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease

Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have ...

Momenta shift to new drugs pays off with $6.5 billion J&J buyout

Momenta shift to new drugs pays off with $6.5 billion J&J buyout

Once a leader in biosimilar development, Momenta pivoted toward developing treatments for autoimmune diseases, including one that drew J&J's interest.

Gaining momentum, Johnson & Johnson acquires Momenta for $6.5B cash

Gaining momentum, Johnson & Johnson acquires Momenta for $6.5B cash

The pace of biopharma mergers and acquisitions has quickened with Johnson & Johnson’s $6.5 billion all-cash acquisition of Momenta Pharmaceuticals Inc. Bringing Momenta into the fold ...

Advances in the Battle Against Autoimmune Disease

Advances in the Battle Against Autoimmune Disease

Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.

AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets

AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets

AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals for ...

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.

Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case–control and population case–control design

Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case–control and population case–control design

COVID-19 epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19. Among those, emerged the ...

Top 20 Biopharma M&A of 2020 by Total Deal Value

Top 20 Biopharma M&A of 2020 by Total Deal Value

#post_contentBiopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of ...

Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More

Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More

The market for drugs for rare or “orphan” diseases continues to grow. An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12

The top 5 pharma M&A deals of 2020

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% ...

What Are Common Symptoms of Autoimmune Disease?

What Are Common Symptoms of Autoimmune Disease?

Fatigue, joint pain and skin problems are some symptoms of autoimmune diseases.